Result of a Phase 3 Randomised Multicenter Study Comparing Pixantrone plus Rituximab with Gemcitabine plus Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation

被引：0

作者：

Salles, Gilles Andre ^{[1
]}

Jurczak, Wojciech ^{[2
]}

Andorsky, David J. ^{[3
]}

Quick, Donald P. ^{[4
]}

Singer, Jack W. ^{[5
]}

Singh, Simran Bedi ^{[5
]}

Wang, Lixia ^{[6
]}

Egorov, Anton ^{[7
]}

Gabarroca, Christine ^{[7
]}

Pettengell, Ruth ^{[8
]}

机构：

[1] Ctr Hosp Lyon Sud, Hematol Dept, Pierre Benite, France

[2] Jagiellonian Univ, Krakow, Poland

[3] US Oncol Res, Rocky Mt Canc Ctr, Boulder, CO USA

[4] Joe Arrington Canc Res Treatment Ctr, Lubbock, TX USA

[5] CTI Biopharma, Seattle, WA USA

[6] CTI BioPharma Corp, Seattle, WA USA

[7] Inst Rech Int Servier, Suresnes, France

[8] St George Hosp, London, England

来源：

关键词：

D O I：

10.1182/blood-2018-99-112455

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4189

引用

页数：3